Capivast 200 mg Tablet

Description

Capivast 200 mg Tablet contains capivasertib, an oral targeted anticancer medicine classified as an AKT kinase inhibitor. It is used in certain types of advanced or metastatic breast cancer, particularly hormone receptor (HR)-positive and HER2-negative disease with specific genetic alterations in the PI3K/AKT/PTEN pathway. Capivasertib is typically prescribed in combination with other oncology medicines, such as endocrine therapy, depending on the treatment plan recommended by a qualified healthcare professional. Capivasertib works by inhibiting AKT, a key enzyme involved in cell signaling pathways that regulate tumor cell growth, survival, and metabolism. Abnormal activation of the AKT pathway can contribute to cancer progression. By blocking this pathway, the medicine may help slow tumor growth in certain patients when used as prescribed and under medical supervision. Treatment with Ca

Benefits

• Targets the AKT signaling pathway, which plays a role in cancer cell survival and growth

• Part of a precision oncology approach based on tumor molecular characteristics

• Oral tablet formulation suitable for outpatient treatment

• May help slow disease progression in certain patients with HR-positive metastatic breast cancer

• Often used in combination with other anticancer therapies for improved treatment strategies

Indications and Usage

Capivast (capivasertib) may be prescribed for:

• Hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer

• Patients with PI3K/AKT/PTEN pathway alterations

• Use in combination with endocrine therapy (such as fulvestrant) when recommended by an oncologist

• Situations where disease has progressed after prior endocrine therapy

Use is determined by a healthcare professional based on tumor characteristics, genetic testing results, and clinical guidelines.

How it Works

Capivasertib works by inhibiting AKT (protein kinase B), a key component of the PI3K/AKT/mTOR signaling pathway that regulates cell growth, survival, and metabolism. In certain cancers, genetic changes in this pathway can lead to uncontrolled cell proliferation and resistance to standard therapies.

By blocking AKT activity, capivasertib disrupts signals that allow cancer cells to grow and survive. This targeted mechanism may help slow tumor progression, particularly in cancers with PIK3CA, AKT1, or PTEN alterations, when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

• Capivast tablets are taken orally, typically in cycles as directed by a healthcare professional.

• Tablets should be swallowed whole with water.

• Do not crush, split, or chew the tablets.

• The medicine may be taken with or without food, unless directed otherwise.

• Dosage schedules and duration depend on clinical response, tolerance, and physician guidance.

• Regular monitoring may be required during treatment.

Side Effects

Common side effects

• Diarrhea

• Rash or skin reactions

• Nausea

• Fatigue

• Decreased appetite

• Increased blood glucose levels

Serious side effects

• Severe diarrhea or dehydration

• Significant skin reactions

• High blood sugar (hyperglycemia)

• Severe infections

• Allergic reactions

Patients should report unusual or severe symptoms to their healthcare provider promptly.

Warning and Precaution

• Risk of severe diarrhea and dehydration

• Possible skin reactions or rash

• Risk of hyperglycemia (high blood sugar)

• Potential infections due to immune system effects

• May cause fetal harm during pregnancy

• Inform healthcare providers about all medications and supplements before starting treatment

• Use caution in patients with pre-existing metabolic or endocrine conditions

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend scheduled medical appointments and laboratory tests

• Report symptoms such as severe diarrhea, rash, or high blood sugar

• Inform your healthcare provider about all other medications or supplements

• Maintain adequate hydration during treatment

• Do not change or stop treatment without medical advice

Clinical Trial & Approvals

Capivasertib has been evaluated in several clinical trials investigating its effectiveness in advanced breast cancer with PI3K/AKT/PTEN pathway alterations. Studies such as the CAPItello-291 trial evaluated capivasertib in combination with endocrine therapy in patients with HR-positive, HER2-negative advanced breast cancer. Regulatory approvals have been granted in some regions based on these clinical trial results, with ongoing research continuing to explore additional therapeutic uses.

References

• U.S. Food and Drug Administration (FDA) – Capivasertib Drug Information
  https://www.fda.gov

• European Medicines Agency (EMA) – Oncology Medicines Database
  https://www.ema.europa.eu

• National Cancer Institute – Targeted Cancer Therapies
  https://www.cancer.gov

• ClinicalTrials.gov – Studies Evaluating Capivasertib
  https://clinicaltrials.gov

• Drugs.com – Capivasertib Drug Information
  https://www.drugs.com

• CAPItello-291 Clinical Trial Publication
  https://clinicaltrials.gov/study/NCT04305496

Capivast 200 mg Tablet is generally supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import paperwork, depending on local regulations. MedsMonk can assist with documentation guidance where applicable.